Monopar Therapeutics Inc (MNPR)

Currency in USD
45.220
-1.210(-2.61%)
Closed·
After Hours
45.2200.000(0.00%)
·
MNPR Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
MNPR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
44.25545.540
52 wk Range
1.71954.300
Key Statistics
Prev. Close
45.22
Open
45.54
Day's Range
44.255-45.54
52 wk Range
1.719-54.3
Volume
15.52K
Average Volume (3m)
37.5K
1-Year Change
1,324.25%
Book Value / Share
8.77
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MNPR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
63.180
Upside
+39.72%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Monopar Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy

Monopar Therapeutics Inc Company Profile

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Compare MNPR to Peers and Sector

Metrics to compare
MNPR
Peers
Sector
Relationship
P/E Ratio
−16.7x−3.8x−0.5x
PEG Ratio
0.510.010.00
Price/Book
5.2x2.4x2.6x
Price / LTM Sales
-8.6x3.2x
Upside (Analyst Target)
41.1%180.6%42.7%
Fair Value Upside
Unlock18.0%5.8%Unlock

Analyst Ratings

6 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 63.180
(+39.72% Upside)

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.38 / -0.09
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

MNPR Income Statement

People Also Watch

262.48
AVAV
-3.56%
17.590
QBTS
-4.35%
16.8100
QUBT
-5.83%
57.090
ASTS
+0.74%
27.38
OUST
-6.62%

FAQ

What Stock Exchange Does Monopar Therapeutics Trade On?

Monopar Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Monopar Therapeutics?

The stock symbol for Monopar Therapeutics is "MNPR."

What Is the Monopar Therapeutics Market Cap?

As of today, Monopar Therapeutics market cap is 276.53M.

What Is Monopar Therapeutics's Earnings Per Share (TTM)?

The Monopar Therapeutics EPS (TTM) is -3.50.

From a Technical Analysis Perspective, Is MNPR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Monopar Therapeutics Stock Split?

Monopar Therapeutics has split 1 times.

How Many Employees Does Monopar Therapeutics Have?

Monopar Therapeutics has 15 employees.

What is the current trading status of Monopar Therapeutics (MNPR)?

As of 23 Jul 2025, Monopar Therapeutics (MNPR) is trading at a price of 45.22, with a previous close of 45.22. The stock has fluctuated within a day range of 44.26 to 45.54, while its 52-week range spans from 1.72 to 54.30.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.